RxDoctor Payments Data

Carrie Lingro, NP

Psychiatric/Mental Health · Cleveland, OHNPI 1770027195

Payments from drug & device makers

$1,193in general payments, 2019–2025

Across 12 payments — averaging $99.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$273
  • Vanda Pharmaceuticals Inc.$240
  • Johnson & Johnson$150
  • Neurocrine Biosciences, Inc.$125
  • E.r. Squibb & Sons, L.L.C.$122
  • Otsuka America Pharmaceutical, Inc.$106
  • plus $178 from 2 others

What the payments were for

  • Food & beverage$1,193100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,193 in reported general payments places this provider in the 60th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$7,623
Medicare patients
37
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole30$57,329
PerserisRisperidone13$26,566
Abilify MaintenaAripiprazole13$25,620
Invega SustennaPaliperidone Palmitate15$24,728
Aripiprazole72$6,201
Quetiapine Fumarate ErQuetiapine Fumarate40$3,359
Quetiapine Fumarate96$1,726
Lurasidone Hcl18$1,699
Mirtazapine39$1,506
Methylphenidate ErMethylphenidate Hcl11$1,343
Prazosin Hcl60$1,318
Doxepin Hcl26$1,281
Bupropion XlBupropion Hcl54$1,155
Olanzapine58$1,064
Hydroxyzine Hcl48$1,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$106$82,94943 claims
Johnson & JohnsonInvega Sustenna$150$24,72815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →